KLBF Stock Overview
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
PT Kalbe Farma Tbk. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp1,405.00 |
| 52 Week High | Rp2,200.00 |
| 52 Week Low | Rp1,375.00 |
| Beta | 0.19 |
| 1 Month Change | -7.57% |
| 3 Month Change | -10.79% |
| 1 Year Change | -32.45% |
| 3 Year Change | -4.42% |
| 5 Year Change | -9.06% |
| Change since IPO | 12,036.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| KLBF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -3.4% | -2.3% | -0.6% |
| 1Y | -32.5% | -25.0% | 2.8% |
Return vs Industry: KLBF underperformed the ID Pharmaceuticals industry which returned -25% over the past year.
Return vs Market: KLBF underperformed the ID Market which returned 2.8% over the past year.
Price Volatility
| KLBF volatility | |
|---|---|
| KLBF Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in ID Market | 12.0% |
| 10% least volatile stocks in ID Market | 2.3% |
Stable Share Price: KLBF has not had significant price volatility in the past 3 months.
Volatility Over Time: KLBF's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 13,108 | . Vidjongtius | www.kalbe.co.id |
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals and Distribution; and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products.
PT Kalbe Farma Tbk. Fundamentals Summary
| KLBF fundamental statistics | |
|---|---|
| Market cap | Rp65.91t |
| Earnings (TTM) | Rp2.77t |
| Revenue (TTM) | Rp30.45t |
23.5x
P/E Ratio2.1x
P/S RatioIs KLBF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLBF income statement (TTM) | |
|---|---|
| Revenue | Rp30.45t |
| Cost of Revenue | Rp18.90t |
| Gross Profit | Rp11.55t |
| Other Expenses | Rp8.78t |
| Earnings | Rp2.77t |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 59.81 |
| Gross Margin | 37.94% |
| Net Profit Margin | 9.09% |
| Debt/Equity Ratio | 2.5% |
How did KLBF perform over the long term?
See historical performance and comparison